Sino Biopharmaceutical gets FDA IND approval for TQB6426 GPC3 ADC
Sino Biopharmaceutical Limited says the FDA has granted IND approval for TQB6426, a GPC3 ADC, for advanced malignant tumors.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.